Breaking News

Aptamer Enters Development Agreement with Top 3 Global Pharma Company

Will engineer Optimer binders as targeted radiopharmaceuticals for potential therapeutic applications.

Author Image

By: Charlie Sternberg

Associate Editor

Aptamer Group plc, a developer of next-generation synthetic binders for the life sciences industry, has signed a significant development contract with a top 3 global pharmaceutical company to engineer Optimer binders as targeted radiopharmaceuticals for potential therapeutic applications. Dr Arron Tolley, CEO of Aptamer Group, said: “This significant contract win with a top 3 global pharmaceutical company marks a key expansion of our platform into targeted radiopharmaceuticals and poten...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters